PTC's fundamental outlook is supported by a strengthening balance sheet, with D/E improving from 0.74 to 0.46 and deferred revenue surging 93% to $1.4B, indicating robust future revenue visibility. However, revenue growth has been volatile, swinging from -6.8%...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth is volatile, swinging from -6.8% in 2026Q3 to +21.7% in 2026Q2, yet gross margins remain resilient above 80%, peaking at 86.9% in 2025Q4, though operating margins fluctuate widely from 18.5% to 48.5%.
PTC demonstrates robust financial health with 19% revenue growth, 95% earnings growth, 34.4% ROE, and positive free cash flow, trading at a P/E of 11.37 below the sector average.
PTC is a high-growth, high-quality company with a 13.4% 5Y revenue CAGR, improving profitability, and strong pricing power (89/100), indicating a well-managed business.
Partnerships like Toyota Racing Development U.S.A. adopting PTC's Creo CAD and Windchill PLM highlight the company's role in enhancing engineering quality and speed to market.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 29, 2026 | $1.58+0.6% vs $1.57 | $600M-1.9% vs $612M |
Q2 2026 May 6, 2026 | $2.69+28.1% vs $2.10 | $774M+8.7% vs $712M |
Q1 2026 Feb 4, 2026 | $1.92+20.8% vs $1.59 | $686M+7.3% vs $639M |
Q4 2025 Nov 5, 2025 | $3.47+52.9% vs $2.27 | $894M+19.0% vs $751M |
– Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene therapy for Fabry disease.
Standardizes on Creo CAD and Windchill PLM across multiple business units and locations Supports design consistency, configuration control, and traceability for complex defense programs Supports both near‑term operational needs and long‑term growth BOSTON, Sept. 15, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that Fisica Applied Technologies, Inc., a leading defense products manufacturer of airborne and ground-based antennas; electromagnetic systems and simulators; and ruggedized batteries, has selected the PTC Creo® computer-aided design (CAD) and Windchill® product lifecycle management (PLM) solutions for product design and development across its engineering environment.
PTC Inc. trades at a depressed valuation after a 37% sell-off, despite underlying ARR growth of 9% and raised full-year guidance. Reported revenue masks business strength; deferred ARR for fiscal 2027 is double last year's level, and improved sales execution is driving retention and competitive wins. New pricing structures embed 3%-4% annual increases, providing a gradual tailwind as contracts renew over the next several years.
Amundi reduced its holdings in PTC Inc. (NASDAQ: PTC) by 45.1% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 947,662 shares of the technology company's stock after selling 777,893 shares during the period. Amundi owned approximately 0.87% of
Benchmark PTC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for PTC Inc. (PTC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $140.00 | $16.17B | 23.03 | 19.18% | 26.8% | 20.85% | — | |
| $302.95 | $83.56B | 74.62 | 14.12% | 23.61% | 22.88% | — | |
| $409.24 | $78.36B | 50.90 | 15.12% | 11.43% | 3.57% | — | |
| $219.62 | $46.37B | 41.99 | 17.53% | 21.08% | 52.5% | — | |
| $363.93 | $36.73B | 25.63 | 12.26% | 30.24% | 12.94% | — | |
| $427.19 | $47.54B | 55.70 | 0.97% | 13.38% | 32.94% | — |
PTC Inc. (PTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
PTC Inc. (PTC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
May 6, 2026·SEC
Mar 16, 2026·SEC
Get notified when PTC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PTC Inc. (PTC) stock FAQ — growth, dividends, profitability & financials explained
PTC Inc. (PTC) reported $2.95B in revenue for fiscal year 2025. This represents a 392% increase from $600.1M in 1996.
PTC Inc. (PTC) grew revenue by 19.2% over the past year. This is strong growth.
Yes, PTC Inc. (PTC) is profitable, generating $1.22B in net income for fiscal year 2025 (26.8% net margin).
PTC Inc. (PTC) has a return on equity (ROE) of 20.9%. This is excellent, indicating efficient use of shareholder capital.
PTC Inc. (PTC) generated $935.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
